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Two antigenically and genetically distinct lineages of influenza B viruses, represented by the reference strains B/Victoria/
2/1987 and B/Yamagata/16/1988, have cocirculated in humans since at least 1983. Between 1992 and 2000, Victoria lineage
viruses were detected only in eastern Asia. From March to September of 2001 and during the 2001–2002 influenza season,
Victoria lineage viruses were detected for the first time in a decade in several countries including Canada, USA, Italy,
Netherlands, Norway, Philippines, India, and Oman. Phylogenetic analysis of the hemagglutinin (HA) gene of these viruses
revealed that the viruses fell into two distinct clades: one group, represented by the reference strain B/Hong Kong/330/2001,
contained viruses sharing three signature amino acids, Arg116, Asn121, and Glu164, while the other group of viruses,
represented by B/Oman/16296/2001, shared Thr121 compared to the previous reference strain, B/Shandong/7/97. A number
of the viruses in the latter group have been found to be reassortants having a Victoria lineage HA and a Yamagata lineage
NA. In the current 2001–2002 season, Victoria-like viruses have now been associated with outbreaks in Asia, Europe, and
North America. The reemergence of these Victoria lineage viruses worldwide, the fact that the majority of the B/Victoria-like
isolates have poor cross-reactivity to B/Sichuan/379/99-like viruses in current vaccines, and the lack of exposure of young
children in many areas of the world to these viruses has resulted in a World Health Organization Northern Hemisphere
recommendation for the inclusion of a B/Victoria-like strain in vaccines for the 2002–2003 influenza season. © 2002 ElsevierIntroduction. Two antigenically and genetically distinct
lineages of influenza B viruses have cocirculated and
caused disease in humans since at least 1988 (1, 2).
These two phylogenetic groups, represented by the ref-
erence strains B/Victoria/2/1987 (Victoria) and B/Yama-
gata/16/1988 (Yamagata), are so different antigenically
as to offer little or no postinfection cross-neutralizing
antibody response in ferrets (3). Furthermore, in immu-
nologically unprimed children, vaccination with a Yama-
gata-like vaccine strain did not induce detectable hem-
agglutination-inhibiting (HI) or neutralizing antibody to
Victoria-like viruses (4). This lack of antigenic cross-
reactivity has made the designation of a type B vaccine
strain problematic in seasons when viruses of both lin-
eages circulate since influenza virus vaccines are cur-
rently formulated to include only a single strain of influ-
enza B virus; the WHO influenza vaccine recommenda-
tions for the Northern Hemisphere 1999–2000 seasonand the Southern Hemisphere 2000 season proposed
either a Yamagata-like or a Victoria-like type B compo-
nent, depending on local conditions (5, 6).
Influenza viruses of the Victoria lineage were the pre-
dominant type B strains circulating worldwide in the
1980s with the Yamagata lineage becoming the dominant
type B virus in the early 1990s (3, 7). Since 1991, Victoria
lineage viruses have been isolated infrequently and
been limited almost entirely to eastern Asia (5, 8–11). In
this article we describe the reappearance outside of East
Asia of Victoria lineage viruses in the spring and summer
of 2001 and the 2001–2002 season as two distinct phy-
logenetic groups based on the nucleotide sequence of
the HA1 portion of the genes encoding the hemagglutinin
(HA) surface antigens. Both genetic groups, similar to
their predecessors, lack antigenic cross-reactivity with
cocirculating Yamagata lineage viruses as represented
by the current B/Sichuan/379/99-like vaccine strains.
Results and Discussion. The first Victoria-like isolatesScience (USA)
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associated with the recent increase in activity were re-
ported from Hong Kong SAR, China in January and Feb-
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ruary of 2001, as represented by the B/Hong Kong/330/
2001 (HK330) prototype strain. An isolate previously ob-
tained from Chongqing on the Chinese mainland in
December of 2000 was retrospectively determined to
also be HK330-like. In March of 2001, a single isolate
obtained in Canada had the same antigenic character-
istics as the Asian Victoria lineage isolates. Upon inves-
tigation, this virus, designated B/Canada/464/2001, was
deemed to be travel-related with infection originally con-
tracted in China. In the absence of other cases in North
America, it was considered an isolated case. However, in
April and May 2001, an outbreak of respiratory illness
caused by this new variant was identified in Hawaii,
marking the first documented sustained circulation of the
Victoria lineage outside of east Asia since the early
1990s. Similar viruses continued to be isolated in Hawaii
through June 2001, but were not detected elsewhere in
the U.S. or Canada during this time. Of a total of 149
influenza B virus isolates characterized antigenically at
CDC from April to September of 2001, 27 (18%) were
HK330-like. Table 1 shows the results of HI testing of
representative Victoria-like and Yamagata-like isolates
FIG. 1. Dendrograms showing the phylogenetic relationships of the hemagglutinin (HA1) and neuraminidase (NA) genes from recent human type
B influenza isolates. The nucleotide sequences were compared to other type B influenza sequences available from GenBank using the sequence
analysis software of the University of Wisconsin Genetic Computer Group (19) and mapped into a phylogenetic tree using the Phylogeny Inference
Package, version 3.5 (20). Bootstrap values for nodes occurring in 95% or more of multiple bootstrap replicates are given immediately to the left of
the node. (A) Dendrogram for the HA1 fragment of the HA gene. (B) Dendrogram for the NA gene. Arrows denote the Northern Hemisphere vaccine
strains recommended by WHO for the 2001–2002 and 2002–2003 influenza seasons (B/Sichuan/379/1999 and B/Hong Kong/330/2001, respectively).
The stars mark the isolates having a Victoria-lineage HA and a Yamagata lineage NA. GenBank Accession Nos. for the sequences used are
AF532525–AF523566 and AY139033–AY139081.
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TABLE 1
Hemagglutination Inhibition Reactions of Influenza Type B Viruses of the Yamagata and Victoria Lineagesa
Strain designation
Reference antisera
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B/Sichuan/379/99 12/02/99 Y 640 1280 320 20 5 20 320 10
B/Shizuoka/15/2001 01/17/01 Y 320 1280 640 10 5 10 320 10
B/Johannesburg/69/2001 06/12/01 Y 320 1280 320 10 5 10 160 10
B/Beijing/243/97 01/09/97 V 20 10 5 320 160 1280 10 80
B/Hong Kong/22/2001 01/18/01 V 10 10 5 160 640 640 5 640
B/Hong Kong/330/2001 04/09/01 V 10 5 5 160 160 640 5 160
B/Taiwan/97271/2001 12/10/01 Y 160 640 320 5 5 5 320 5
B/New York/47/2001 12/31/01 Y 320 640 320 10 5 5 320 5
B/Texas/3/2002 01/29/02 Y 640 1280 320 10 20 10 640 5
B/Oman/16296/2001 10/03/01 V 10 20 10 160 160 320 5 160
B/Philippines/5072/2001 10/26/01 V 5 5 5 40 80 160 5 40
B/Malaysia/83077/2001 10/30/01 V 5 5 5 80 80 160 5 160
B/India/7600/2001 12/05/01 V 20 10 10 80 80 160 5 160
B/Hong Kong/1351/2002 01/17/02 V 5 5 5 160 160 320 5 80
B/New York/1/2002 01/28/02 V 10 10 10 80 160 160 5 160
a HI tests conducted as described in Kendal et al. (18). Titers are presented as reciprocals of the highest dilution showing complete hemagglu-
tination inhibition. Homologous titers (reference antiserum vs. the homologous antigen) are underlined.
b Month/Day/Year.
c Y  Yamagata/16/88-like; V  Victoria/2/87-like.
d Ferret postinfection antisera.
e Antigenically equivalent to B/Shandong/7/1997.
f Sheep antisera.
FIG. 1—Continued
illustrating the poor antigenic cross-reactivity between
the two lineages.
In September, October, and November of 2001, B/Vic-
toria lineage isolates obtained from the Philippines,
Oman, and India were characterized at CDC. Those from
the Philippines (represented by B/Philippines/5072/2001)
were HK330-like, while those from Oman and India (rep-
resented by B/Oman/16296/2001 and B/India/7600/2001)
more closely resembled the antigenically equivalent ref-
erence strains B/Beijing/243/97 and B/Shandong/7/97
(Table 1). Since the beginning of 2002, Victoria-like vi-
ruses have been reported from North America and Eu-
rope (9), clearly demonstrating that the Victoria lineage
has begun to circulate worldwide.
To further characterize the newly reemergent Victoria-
like influenza B isolates at the molecular level, represen-
tative viruses of the Victoria lineage isolated in 2000–
2002, including seven from the Spring 2001 Hawaii out-
break, viruses from Canada and the United States
mainland, and viruses from South and East Asia, were
chosen for nucleotide sequence analysis. For compari-
son, representative contemporary viruses of the Yama-
gata lineage were also included. Figure 1 shows the
phylogenetic relationships of the hemagglutinin and
neuraminidase genes from these viruses. For both the
HA1 and NA genes, the isolates associated with the first
reported outbreaks in 2001, as represented by B/Hong
Kong/330/2001, fell into a distinct clade most closely
related to the 1997 isolate, B/Taiwan/217/97. This clade
was distinct from the clade containing the majority of
previously isolated Victoria-like viruses, including the
reference strains B/Beijing/243/97 and B/Shandong/7/97.
However, it should be noted that a second group of
recent Victoria lineage isolates characterized for the
present study, B/Sichuan/34/2001, B/Taiwan/1484/2001, and
viruses from Oman, India, Malaysia, and the United States,
fell within the previously dominant clade defined by the
majority of isolates from 1997 to 2000, demonstrating that
these viruses have also begun to circulate outside of their
previous East Asia confines. Viruses from these two clades
were phylogenetically distinct (Fig. 1) but were antigenically
similar (Table 1). Victoria lineage type B viruses of both
clades continue to be isolated with neither appearing at
present to become the dominant group.
Table 2 shows the differences in HA1 amino acids
among the type B viruses compared to the sequence of
the B/Shandong/7/97 reference strain. The phylogenetic
clade containing the Hong Kong/330/2001-like (HK-like)
viruses is distinguished by three signature amino acids,
Arg116, Asn121, and Glu164, when compared to previ-
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Amino Acid Differences in Influenza B HA1 Molecules Compared to B/Shandong/7/97 Virus
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TABLE 3
Amino Acid Differences in Victoria Lineage Influenza B NA Molecules Compared to B/Shandong/7/97 Virus
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TABLE 4
Amino Acid Differences in Victoria Lineage Influenza B NB Molecules Compared to B/Shandong/7/97 Virus
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TABLE 5
Influenza B Virus Strains Used in the Present Study
Strain Isolation date Passage historya
GenBank sequence Accession Number
HA NA
B/Hong Kong/70/96 06/18/96 C4 AF532556 AY139050
B/Sichuan/281/96 11/29/96 E2 AY139033 AY139051
B/Guangzhou/7/97 01/16/97 C3 AF532533 AY139052
B/Taiwan/217/97 02/17/97 C4 AY139035 AY139053
B/Osaka/547/97 unk. C2 AY139036 AY139054
B/Bangkok/54/99 02/01/99 C5 AF532528 AY139055
B/Bangkok/34/99 02/21/99 C5 AF532527 AY139056
B/Nanchang/1/2000 01/17/00 E3 AF532564 ND
B/Texas/1/2000 02/10/00 C2 AY139037 AY139058
B/Hong Kong/557/2000 10/04/00 orig. AF532553 AY139057
B/Alaska/16/2000 11/22/00 E2 AF532526 AY139059
B/Wuhan/356/2000 12/13/00 Ex AY139038 AY139060
B/Chongqing/3/2000 12/26/00 C1E2 AF532530 ND
B/Wuhan/2/2001 01/01/01 E3 AY139039 AY139061
B/Hong Kong/6/2001 01/08/01 C3 AF532554 AY139062
B/Hong Kong/22/2001 01/18/01 C3 AF532547 AY139063
B/Hong Kong/28/2001 01/22/01 C3 ND AY139064
B/CNIC/27/2001 02/05/01 C2 AF532532 ND
B/Hong Kong/112/2001 02/20/01 C3 AF532543 ND
B/Hong Kong/123/2001 02/23/01 C2 AF532544 ND
B/Canada/464/2001 03/05/01 C2 AF532531 AY139065
B/Hong Kong/329/2001 04/09/01 C3 AF532548 ND
B/Hong Kong/330/2001 04/09/01 E2 AF532549 AY139066
B/Hong Kong/335/2001 04/11/01 C3 AF532550 ND
B/Hong Kong/336/2001 04/11/01 C3 AF532551 ND
B/Yunnan/123/2001 04/18/01 E4 AY139040 ND
B/Hawaii/9/2001 04/19/01 C3 AF532541 ND
B/Hawaii/10/2001 05/09/01 C3 AF532535 AY139067
B/Hawaii/10e/2001 05/09/01 E2 AF532534 ND
B/Hawaii/35/2001 05/19/01 C3 AF532537 ND
B/Sichuan/317/2001 05/24/01 E3 AY139034 AY139068
B/Taiwan/1484/2001 05/25/01 C3 AY139041 ND
B/Hawaii/37/2001 06/01/01 Cx AF532539 ND
B/Hawaii/36/2001 06/03/01 C3 AF532538 AY139069
B/Hawaii/38/2001 06/11/01 Cx AF532540 ND
B/Hong Kong/497/2001 06/11/01 C3 AF532552 ND
B/Hawaii/26/2001 06/26/01 C3 AF532536 ND
B/Brazil/952/2001 07/05/01 Ex AF532529 AY139070
B/Argentina/69/2001 07/13/01 C3 AF532525 AY139071
B/Hong Kong/666/2001 08/29/01 C3 AF532555 ND
B/Oman/16299/2001 09/22/01 C3 AY139042 ND
B/Oman/16291/2001 09/26/01 C3 AF532566 ND
B/Oman/16305/2001 09/26/01 C3 AY139043 ND
B/Oman/16296/2001 10/03/01 C3 AY139044 AY139072
B/Philippines/93079/2001 10/15/01 Cx AY139045 ND
B/India/772767/2001 10/23/01 Cx AF532561 ND
B/Philippines/5072/2001 10/26/01 Cx AY139046 ND
B/Malaysia/83077/2001 10/30/01 Cx AF532563 AY139073
B/India/7569/2001 11/07/01 Cx AF532558 ND
B/India/7526/2001 11/10/01 Cx AF532557 ND
B/India/7605/2001 11/10/01 Cx AF532560 ND
B/India/7600/2001 12/05/01 Cx AF532559 ND
B/Taiwan/97271/2001 12/10/01 Cx AY139047 ND
B/New York/47/2001 12/31/01 Cx AY139048 ND
B/Hong Kong/1115/2002 01/15/02 E5 AF532542 ND
B/Hong Kong/1351/2002 01/17/02 E1 AF532545 AY139074
B/Hong Kong/1434/2002 01/18/02 E3 AF532546 ND
B/New York/1/2002 01/28/02 Cx AF532565 AY139075
B/Maryland/1/2002 unk. Cx AF532562 AY139076
a C  tissue culture; E  Embryonated hens’ eggs.
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ously circulating Victoria lineage isolates. Amino acid
164 has been demonstrated to be within an epitope
critical to the antigenicity of Victoria lineage viruses
which is absent in viruses of the Yamagata lineage (12).
The second phylogenetic clade containing the Oman/
16296/2001-like (Oman-like) viruses is distinguished by
Thr121 compared to B/Shandong/7/97, a change which is
shared with the prototype B/Victoria/2/87 virus. Variation
in the amino acids defining the potential N-linked glyco-
sylation site at amino acids 197–199 was apparent in
viruses from both the HK-like and the Oman-like clades
(Table 2). The presence or absence of this site, which is
near the putative receptor-binding region, is affected by
the host cell in which the virus is grown, with viruses
cultivated in embryonated eggs usually lacking the site
(13). The results obtained from these recent Victoria-
lineage viruses confirm that observation.
Table 3 shows the deduced amino acid sequence
differences among the NA genes from isolates of the
Victoria-like viruses compared to the B/Shandong/7/97
sequence. As shown in Fig. 1, similar to the HA1 mole-
cules, the neuraminidase genes could be separated into
two phylogenetic clades. Viruses belonging to the HK-
like clade are defined by five distinct amino acids (Table
3). Four of these residues, Thr50, Ser54, Phe60, and
Lys69, are in the stalk region of the molecule; the only
residue of the five present in the globular head is Thr436.
Three other residues, Lys250, Ser345, and Lys360, are
also seen in the sequence of the phylogenetically dis-
tinct B/Hong Kong/70/96. The Oman-like viruses have an
NA gene more closely related to those of the previously
dominant Victoria-like strains circulating in East Asia
being different only at position 54 (Cys to Tyr).
The deduced amino acid sequences of the Victoria-
lineage NB glycoproteins vary in a manner similar to the
NA glycoproteins (Table 4). The NB of the recent HK-like
isolates can be distinguished by amino acids Phe62 and
Lys96; an additional three signature residues are shared
with Taiwan/217/97 and/or Hong Kong/70/96 (Val21,
Arg65, and Lys71). The NB of the two Oman-like viruses
sequenced are distinguished by a leucine at position 99
but because of the small sample size it should only be
considered a tentative feature at present. Asn47 is com-
mon to recent isolates of both clades and is shared with
Hong Kong/70/96 and Taiwan/217/97 (Table 4). Because
NB is much less well characterized than the HA and NA
glycoproteins, it is not practical at present to speculate
on the possible significance of the changes noted.
Analysis of the NA genes of the current isolates re-
vealed that the B/New York/1/2002 isolate, which clearly
has a Victoria-like HA (Fig. 1A and Table 2), has a neur-
aminidase gene of the Yamagata lineage (Fig. 1B). This
has also been seen in other 2002 isolates such as
Maryland/1/2002 and Hong Kong/1351/2002 (Fig. 1).
Such reassortment between Yamagata- and Victoria-lin-
eage type B viruses has been reported before (14, 15)
and similar reassortment has been seen between cocir-
culating clades of type A H3N2 viruses (16). More iso-
lates will need to be characterized before the relative
frequency of this apparent reassortment event and its
effects on antigenicity can be determined.
It is not known why the Victoria lineage viruses were
confined to East Asia for the past 10 years or why they
have now begun to spread beyond. A similar phenome-
non was observed within the influenza type A H1N1
viruses where A/New Caledonia/20/99 lineage viruses,
which are currently the dominant strain, were limited to
Asia for four years while A/Bayern/262/95 lineage vi-
ruses circulated worldwide (17; CDC, unpublished data).
The appearance of new genetic variants of the Victoria
lineage of type B influenza virus with a demonstrated
ability to spread beyond Asia suggests that these viruses
may have the capacity to become the dominant sublin-
eage of influenza B viruses worldwide. The fact that the
influenza B/Victoria-lineage isolates examined from the
2000–2001 and 2001–2002 seasons, similar to all viruses
of the Victoria lineage, show extremely poor cross-reac-
tivity to recent B/Sichuan/379/99-like vaccine strains and
the spread of these viruses led the WHO to recommend
the inclusion of a representative of this new antigenic
group in the vaccine (9). Influenza B viruses are clearly
deserving of continued intensive surveillance in coming
seasons to monitor the spread and impact of these
Victoria lineage variants in areas where populations are
susceptible. The demonstrated ability of these two major
antigenic groups to undergo reassortment of their sur-
face antigens complicates selection of an influenza B
vaccine strain and necessitates more rigorous monitor-
ing of both HA and NA genes to determine the dominant
genotype(s) in different locations around the world.
Materials and Methods. Viruses. Influenza B viruses
used in this study, their isolation dates, and passage
history are listed in Table 5.
Hemagglutination inhibition tests. HI tests were per-
formed as described in Kendal et al. (18).
Nucleotide sequence analysis. Viral RNA was ex-
tracted and purified from culture supernates using either
the QIAmp Viral RNA mini kit (Qiagen, Santa Clara, CA) or
an automated MagNAPure LC instrument using the Mag-
NAPure LC Total Nucleic Acid Isolation kit (Roche Diag-
nostics, Indianapolis, IN). RT-PCR was conducted using
the Access RT-PCR System kit (Promega Corp., Madison,
WI) and the cDNA products purified using the QIAquick
PCR purification kit (Qiagen, Santa Clara, CA). Sequenc-
ing reactions were performed using the ABI BigDye ter-
minator cycle sequencing kit with reaction products re-
solved on either an ABI 3100 Genetic Analyzer or an ABI
377 DNA Sequencer (Applied Biosystems, Foster City,
CA). Sequences of the primers used for amplification and
sequencing are available upon request.
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DNA sequence analysis was performed using the se-
quence analysis software of the University of Wisconsin
Genetic Computer Group (19). Bootstrap confidence val-
ues were determined using 100 replicates before deter-
mining phylogenetic distances which were mapped into
neighbor-joining trees using the Phylogeny Inference
Package, version 3.5 (20).
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